LNTH
Lantheus Holdings, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$100.55
−0.25%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$100.77
From 52W high−9.37%
Volume960822.00
Market cap$6.57B
P/E (TTM)23.9x
P/S (TTM)4.2x
Div yield—
Key dataSep 18, 2026
Open
$100.77
From 52W high
−9.37%
Volume
960822.00
Market cap
$6.57B
ValuationView details →
P/E (Fwd)
17.8x
EV/EBITDA
14.2x
P/E (TTM)
23.9x
RSI (14)
47.6
MomentumView details →
1D Return
−0.25%
YTD Return
+51.28%
SummaryUpdated Jun 1, 2026
Lantheus Holdings, Inc. (NASDAQ:LNTH) is a specialized pharmaceutical company founded in 1956 and headquartered in North Billerica, Massachusetts. The company develops, manufactures, and commercializes diagnostic and therapeutic radiopharmaceuticals that assist clinicians in diagnosing and treating heart disease, cancer, and other conditions. Originally focused on traditional nuclear medicine products, Lantheus has transformed into a leading player in the rapidly growing radiopharmaceutical oncology market, particularly through its blockbuster PSMA PET imaging agent PYLARIFY, which became the first radiopharmaceutical to exceed $1 billion in annual sales.
Similar companies
Latest newsMore news →
Kahn Swick & Foti, LLC is investigating the proposed sale of Lantheus Holdings, Inc. to Curium US Holdings LLC, under which Lantheus shareholders would receive $102.50 per share in cash plus non-transferable Contingent Value Rights worth up to $12.00 per share.10d agoLantheus Alpha Therapy, LLC, a director and 10% owner of Perspective Therapeutics, sold 42,129 shares of common stock for $131,219 on September 2, 2026.15d agoHalper Sadeh LLC announced it is investigating the sale of Lantheus Holdings, Inc. to Curium US Holdings LLC for $102.50 per share in cash plus contingent value rights of up to $12.00 per share.22d ago